Investor Presentaiton
IBI-362 (GLP-1/GCGR): A Weekly GLP-1/GCGR Dual Agonist
IBI-362 Differentiated Advantages
·
•
Weekly injectable OXM analog via optimized ratio of activation of
GLP-1 and Glucagon receptor vs. binding GLP-1 only
•
Dual activation of GLP-1/GCGR may bring multiple metabolic and
CV benefit include:
.
1) blood glucose reduction and weight loss
2)
blood pressure and Lipid spectrum improvement;
3)
improvement on Liver fat accumulation, inflammation and fibrosis
4) potential CV risk reduction
Pre-clinical Highlights
Blood Glucose (mg/dL)
300
100
Glucose after a single treatment
Rx
Dark
Dark
Dark
0
12
24
48
60
72
84
96
Time Post Injection (hr)
STZ-Vehicle, N=7
LSN3305677-30nmol/kg
LSN3326311-30nmol/kg
Semaglutide-30nmol/kg
Non-STZ-Vehicle, N=7
LSN3305677: Co-agonist
LSN3326311: Q3E mutant of LSN3305677, a GLP-1 agonist
LSN3119036: Semaglutide, a FA acylated GLP-1 agonist
Cumulative Weight Change (%)
-20
-30
-40
RX
RX
Clinical Highlights
Promising data of IBI-362 in both weight loss and glucose
control
The preliminary results of IBI-362 in
of IBI-362 in patients with
obesity/overweight and patients in Type 2 Diabetes were very
impressive, demonstrated good tolerability/safety profile and
very promising efficacy on HbA1c reduction and weight loss
after 12-week treatment
IBI-362 Development Program Overview
--11%
-12%
Clinical
-18%
-20%
-32%
VRX VRX VRX √/RX
-50
0
3
6
9
12
15
18
Treatments Day
Vehicle, N=7
3305677, 15 nmol (68 ug)/kg
3305677, 30 nmol (137 ug)/kg
3326311, 30 nmol (137 ug)/kg
Semaglutide, 60 nmol (247 ug)/kg
GLP-PEG40K, 22.5 nmol (995 ug)/kg
LSN3305677: Co-agonist
LSN3326311: Q3E mutant of LSN3305677, a GLP-1 agonist
progress
2021 plan
Completed patient enrolment of Phase 1b trial in China in
overweight or obese subjects in 2020
Completed patient enrolment of Phase 1b trial in China in diabetic
patients in Jan 2021
In Jun 2021, plan to present Phase 1b study data in obesity at the
annual meeting of American Diabetes Association
Around the end of 2021, plan to present Phase 1b study in diabetic
patients at academic meetings
In 2021, plan to start Phase 2 trial in obesity subjects
In 2021, plan to start Phase 2 trial in diabetic patients
First-in-class OXM3 in China in face of 130m diabetics patients with the potential to bring additional benefit over glucose control incl. weight
losses and other metabolic improvements. Increasing obesity groups with no prescription drugs in China. IBI-362 has demonstrated strong
weight deduction effect in the Phase 1b trial.
Innovent
Confidential
Copyright©2021 Innovent Biologics
29
29View entire presentation